Atara Biotherapeutics(US:ATRA) Globenewswire·2026-03-23 20:51Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Atara Biotherapeutics, Inc. due to allegations of violations of federal securities laws related to misleading statements and undisclosed manufacturing issues affecting the company's product approval process [4][6]. Group 1: Legal Investigation and Class Action - Faruqi & Faruqi is encouraging investors who suffered losses in Atara between May 20, 2024, and January 9, 2026, to discuss their legal rights [1]. - A federal securities class action has been filed against Atara, with a deadline of May 22, 2026, for investors to seek the role of lead plaintiff [4][8]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [5]. Group 2: Allegations Against Atara - The complaint alleges that Atara and its executives made false and misleading statements regarding manufacturing issues and the regulatory prospects of their product, tabelecleucel [6]. - Specific allegations include that manufacturing issues and deficiencies in the ALLELE study made FDA approval unlikely, overstating the product's regulatory prospects, and increasing the risk of regulatory scrutiny [6]. - The complaint asserts that these issues would likely have a significant negative impact on Atara's business and financial condition [6]. Group 3: Stock Price Impact - Following the announcement of a Complete Response Letter (CRL) from the FDA regarding the EBVALLO™ Biologics License Application, Atara's stock price fell by $7.79 per share, or 56.99%, closing at $5.88 per share on January 12, 2026 [7].